To the best of our knowledge, this is the first study in patients with LA-NSCLC describing pathologic regression as a function of EGFR mutation in surgical specimens following aggressive NA-ChRT using a radiation dose in the neoadjuvant setting similar to the doses used when delivering definitive treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.